PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.92%
Cash & equivalents declining -42.92% while AGEN's grows 4.79%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-42.83%
Cash + STI yoy ≥ 1.5x AGEN's -23.97%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.38%
≥ 1.5x AGEN's -22.73%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-9.44%
Below half AGEN's 14.71%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.57%
≥ 1.5x AGEN's -1.72%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-39.92%
≥ 1.5x AGEN's -14.95%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
31.92%
Less than half of AGEN's -24.26%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.79%
Less than half of AGEN's -53.42%. David Dodd sees fewer expansions in other current obligations.
-7.19%
Less than half of AGEN's -40.87%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.19%
Less than half of AGEN's 32.89%. David Dodd sees far fewer liability expansions relative to competitor.
1.19%
Above 1.5x AGEN's 0.06%. Michael Burry suspects heavy new equity expansion or dilution.
-6.33%
≥ 1.5x AGEN's -3.90%. David Dodd sees higher yoy retained profits than competitor.
-55.74%
Similar yoy to AGEN's -70.27%. Walter Schloss sees parallel comprehensive income changes.
No Data
No Data available this quarter, please select a different quarter.
-181.05%
≥ 1.5x AGEN's -52.90%. David Dodd sees stronger capital base growth than competitor.
-39.92%
≥ 1.5x AGEN's -14.95%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.34%
Less than half of AGEN's -7.98%. David Dodd sees better deleveraging or stronger cash buildup than competitor.